NeuroPace, Inc., a medical device company focused on improving the lives of individuals with epilepsy, has announced that an abstract from its Post-approval Study of the RNS System will be ...

When you hear the word epilepsy, what comes to mind? For many, it rsquo;s a vague image of someone having a seizure ndash; ...

After experiencing seizures every other week, Christine Kauzen has been seizure-free for months since receiving a rare ...

One of the key developments is the potential expansion of indications for the RNS System. NeuroPace is targeting the treatment of idiopathic generalized epilepsy (IGE), with plans to submit an FDA ...

using real-world data from children treated with RNS therapy across 27 pediatric epilepsy centers to support an expansion in indication for use; FDA submission anticipated in second half of 2025 ...

Fourth Quarter 2024 Financial Results Total revenue in the fourth quarter of 2024 grew 19% to $21.5 million, compared with $18.0 million in the fourth quarter of 2023. The Company’s revenue growth was ...

NeuroPace is known for its innovative RNS System, the first brain-responsive platform that provides personalized treatment to manage seizures in patients with drug-resistant epilepsy, potentially ...

“We are pleased by the interest in our recent financing and the confidence it shows in our mission to transform the lives of people suffering from drug-resistant epilepsy through RNS ® therapy. We are ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

“We have several ongoing clinical programs examining the RNS System in expanded patient populations and new indications in epilepsy that are expected to announce data or have regulatory events ...

RN reviews safety, expectations ... Buchhalter, PhD MD, is the former director of the pediatric epilepsy program in the Mayo Clinic Department of Neurology, Rochester, MN.